Analysis links SERMs to breast cancer prevention benefit

05/1/2013 | MyHealthNewsDaily.com · PhysiciansBriefing.com

Taking selective estrogen receptor modulators such as tamoxifen and raloxifene after menopause reduces by 38% a woman's risk of developing any kind of breast cancer for 10 years, according to an analysis of data from nine studies. The estrogen-blocking drugs particularly lowered the risk of estrogen-receptor positive breast cancer, researchers found. The study appeared online in The Lancet.

View Full Article in:

MyHealthNewsDaily.com · PhysiciansBriefing.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA